Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

The specification generally relates to compounds of Formula (I):

##STR00001##

or a stereoisomer or pharmaceutically salt thereof, wherein G, G.sub.a, G.sub.b, X, Y, R.sup.1, R.sup.2, Q.sup.1, Q.sup.2, and Q.sup.3 have any of the meanings defined herein, together with compositions containing them and their use in therapy. The compounds are inhibitors of the polymerase, DNA polymerase theta (Pol or POLQ), and are thereby particularly useful in the treatment of cancer.

Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

The specification generally relates to compounds of Formula (I): ##STR00001##
or a stereoisomer or pharmaceutically salt thereof, wherein G, G.sub.a, G.sub.b, X, Y, R.sup.1, R.sup.2, Q.sup.1, Q.sup.2, and Q.sup.3 have any of the meanings defined herein, together with compositions containing them and their use in therapy. The compounds are inhibitors of the polymerase, DNA polymerase theta (Pol or POLQ), and are thereby particularly useful in the treatment of cancer.

The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.

The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.